​

Charles River Laboratories (CRL) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

CRL Stock Forecast

Charles River Laboratories (CRL) stock forecast, based on 36 Wall Street analysts, predicts a 12-month average price target of $191.50, with a high of $200.00 and a low of $174.00. This represents a -1.47% decline from the last price of $194.36.

$170 $191 $212 $233 $254 $275 High: $200 Avg: $191.5 Low: $174 Last Closed Price: $194.36

CRL Stock Rating

Charles River Laboratories stock's rating consensus is Buy, based on 36 Wall Street analysts. The breakdown includes 1 Strong Buy (2.78%), 24 Buy (66.67%), 11 Hold (30.56%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 36 11 24 1 Strong Sell Sell Hold Buy Strong Buy

CRL Price Target Upside V Benchmarks

TypeNameUpside
StockCharles River Laboratories-1.47%
SectorHealthcare Stocks 15.45%
IndustryDiagnostics & Research Stocks6.89%

Price Target Trends

1M3M12M
# Anlaysts256
Avg Price Target$192.50$190.80$191.50
Last Closing Price$194.36$194.36$194.36
Upside/Downside-0.96%-1.83%-1.47%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Dec, 25198--18
Nov, 25278-118
Oct, 251611--18
Sep, 251512--18
Aug, 25-5121-18
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Dec 01, 2025Kallum TitchmarshMorgan Stanley$185.00$176.095.06%-4.82%
Nov 17, 2025Argus Research$200.00$166.7319.95%2.90%
Oct 17, 2025Ann HynesMizuho Securities$174.00$174.95-0.54%-10.48%
Oct 03, 2025Elizabeth AndersonEvercore ISI$200.00$181.1810.39%2.90%
Oct 02, 2025Luke SergottBarclays$195.00$170.4814.38%0.33%
Sep 09, 2025Jefferies$195.00$157.3823.90%0.33%
Oct 15, 2024Luke SergottBarclays$205.00$193.146.14%5.47%
Oct 14, 2024Jamie ClarkRedburn Partners$151.00$192.97-21.75%-22.31%
Sep 17, 2024Ann HynesMizuho Securities$210.00$206.441.72%8.05%
Aug 08, 2024Justin BowersDeutsche Bank$240.00$200.3419.80%23.48%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Oct 06, 2025William BlairOutperformupgrade
Oct 03, 2025Evercore ISIOutperformOutperformhold
Oct 02, 2025BarclaysEqual-WeightOverweightupgrade
Sep 09, 2025JefferiesHoldBuyupgrade
May 14, 2025Cowen & Co.HoldBuyupgrade
Mar 04, 2025CitigroupSellNeutralupgrade
Oct 23, 2024CLSAUnderperforminitialise
Oct 15, 2024BarclaysEqual-WeightEqual-Weighthold
Oct 01, 2024CitigroupBuySelldowngrade
Aug 08, 2024Deutsche BankBuyBuyhold

Financial Forecast

EPS Forecast

$7 $8 $9 $10 $11 $12 $13 $14 $15 $16 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$7.35$7.77$9.57$9.27-----
Avg Forecast$7.86$10.26$10.89$10.59$10.19$9.88$11.00$12.43$14.23
High Forecast$8.05$10.51$11.15$10.68$10.30$12.56$12.63$15.07$15.26
Low Forecast$7.63$9.96$10.70$10.45$10.12$9.10$9.71$10.39$13.52
Surprise %-6.49%-24.27%-12.12%-12.46%-----

Revenue Forecast

$3B $3B $4B $4B $5B $5B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$2.92B$3.54B$3.98B$4.13B$4.05B----
Avg Forecast$2.89B$3.52B$3.91B$4.11B$4.03B$3.93B$4.16B$4.37B$4.63B
High Forecast$2.94B$3.59B$3.98B$4.12B$4.05B$4.07B$4.18B$4.42B$4.89B
Low Forecast$2.82B$3.44B$3.86B$4.10B$4.02B$3.77B$4.15B$4.31B$4.46B
Surprise %1.18%0.50%1.64%0.55%0.47%----

Net Income Forecast

$50M $200M $350M $500M $650M $800M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$364.30M$390.98M$486.23M$474.62M$93.11M----
Avg Forecast$285.53M$364.08M$454.69M$474.62M$525.43M$557.17M$574.85M$654.91M$732.15M
High Forecast$342.63M$436.89M$545.62M$569.55M$530.07M$646.04M$650.02M$775.34M$785.01M
Low Forecast$228.42M$291.26M$363.75M$379.70M$520.79M$468.30M$499.69M$534.47M$695.76M
Surprise %27.59%7.39%6.94%--82.28%----

CRL Forecast FAQ

Is Charles River Laboratories stock a buy?

Charles River Laboratories stock has a consensus rating of Buy, based on 36 Wall Street analysts. The rating breakdown includes 1 Strong Buy, 24 Buy, 11 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Charles River Laboratories is a favorable investment for most analysts.

What is Charles River Laboratories's price target?

Charles River Laboratories's price target, set by 36 Wall Street analysts, averages $191.5 over the next 12 months. The price target range spans from $174 at the low end to $200 at the high end, suggesting a potential -1.47% change from the previous closing price of $194.36.

How does Charles River Laboratories stock forecast compare to its benchmarks?

Charles River Laboratories's stock forecast shows a -1.47% downside, underperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the diagnostics & research stocks industry (6.89%).

What is the breakdown of analyst ratings for Charles River Laboratories over the past three months?

  • December 2025: 5.56% Strong Buy, 50.00% Buy, 44.44% Hold, 0% Sell, 0% Strong Sell.
  • November 2025: 11.11% Strong Buy, 38.89% Buy, 44.44% Hold, 0% Sell, 5.56% Strong Sell.
  • October 2025: 5.56% Strong Buy, 33.33% Buy, 61.11% Hold, 0% Sell, 0% Strong Sell.

What is Charles River Laboratories’s EPS forecast?

Charles River Laboratories's average annual EPS forecast for its fiscal year ending in December 2025 is $9.88, marking a 0% decrease from the reported $0 in 2024. Estimates for the following years are $11 in 2026, $12.43 in 2027, and $14.23 in 2028.

What is Charles River Laboratories’s revenue forecast?

Charles River Laboratories's average annual revenue forecast for its fiscal year ending in December 2025 is $3.93B, reflecting a -3.02% decrease from the reported $4.05B in 2024. The forecast for 2026 is $4.16B, followed by $4.37B for 2027, and $4.63B for 2028.

What is Charles River Laboratories’s net income forecast?

Charles River Laboratories's net income forecast for the fiscal year ending in December 2025 stands at $557.17M, representing an 498.37% increase from the reported $93.11M in 2024. Projections indicate $574.85M in 2026, $654.91M in 2027, and $732.15M in 2028.